Drug discovery based on genetic and metabolic findings in schizophrenia.
about
NMDA receptor hypofunction induces dysfunctions of energy metabolism and semaphorin signaling in rats: a synaptic proteome study.Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.Antipsychotic drugs activate the C. elegans akt pathway via the DAF-2 insulin/IGF-1 receptor.
P2860
Drug discovery based on genetic and metabolic findings in schizophrenia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Drug discovery based on genetic and metabolic findings in schizophrenia.
@en
type
label
Drug discovery based on genetic and metabolic findings in schizophrenia.
@en
prefLabel
Drug discovery based on genetic and metabolic findings in schizophrenia.
@en
P2093
P2860
P356
P1476
Drug discovery based on genetic and metabolic findings in schizophrenia.
@en
P2093
Donard S Dwyer
Eric J Aamodt
Kathrine Weeks
P2860
P304
P356
10.1586/17512433.1.6.773
P407
P577
2008-11-01T00:00:00Z